Clinical Study

The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis

Table 2

Differences after 3 and 6 months of treatment.

VariableFollow-up visitSimvastatin groupControl group

Early morning stiffness (min)3 month 0.63
6 month 0.996
Tender joint count3 month 0.03
6 month 0.243
Swollen joint count3 month 0.068
6 month 0.288
VAS pain (mm)3 month 0.888
6 month 0.481
Patient global assessment (mm)3 month    0.273
6 month       0.196
Evaluator global assessment (mm)3 month       <0.001
6 month       0.007
HAQ-DI3 month 0.353
6 month 0.149
Erythrocyte sedimentation rate (mm/h)3 month 0.203
6 month 0.751
C-reactive protein (mg/L)3 month 0.055
6 month 0.687
DAS28 ESR3 month 0.009
6 month 0.171
DAS28 CRP3 month 0.02
6 month 0.151
SDAI3 month    0.003
6 month       0.067
CDAI3 month       0.004
6 month 0.068
EULAR response3 month16 (32%)7 (14%)0.033
6 month15 (30%)11 (22%)0.364
Attendance to visit3 month48 (96%)49 (98%)0.560
6 month45 (90%)43 (86%)0.540

Between the breaks, there are 95% confidence interval or percents.